The Tyrosine Phosphatase SHP-1 Regulates Hypoxia Inducible Factor-1α (HIF-1α) Protein Levels in Endothelial Cells under Hypoxia

Stefan K. Alig1,2☯, Yvonn Stampnik1☯, Joachim Pircher1,3, Raffaela Rotter1, Erik Gaitzsch1, Andrea Ribeiro4, Markus Wörnle4, Florian Krötz5, Hanna Mannell1*

1 Walter Brendel Centre of Experimental Medicine, University of Munich, Munich, Germany, 2 Department of Internal Medicine III, University of Munich, Munich, Germany, 3 Department of Internal Medicine I, University of Munich, Munich, Germany, 4 Department of Internal Medicine IV, University of Munich, Munich, Germany, 5 Interventional Cardiology, Starnberg Community Hospital, Starnberg, Germany

☯ These authors contributed equally to this work.
*
hanna.mannell@lrz.uni-muenchen.de

Abstract

Introduction
The tyrosine phosphatase SHP-1 negatively influences endothelial function, such as VEGF signaling and reactive oxygen species (ROS) formation, and has been shown to influence angiogenesis during tissue ischemia. In ischemic tissues, hypoxia induced angiogenesis is crucial for restoring oxygen supply. However, the exact mechanism how SHP-1 affects endothelial function during ischemia or hypoxia remains unclear. We performed in vitro endothelial cell culture experiments to characterize the role of SHP-1 during hypoxia.

Results
SHP-1 knock-down by specific antisense oligodesoxynucleotides (AS-Odn) increased cell growth as well as VEGF synthesis and secretion during 24 hours of hypoxia compared to control AS-Odn. This was prevented by HIF-1α inhibition (echinomycin and apigenin). SHP-1 knock-down as well as overexpression of a catalytically inactive SHP-1 (SHP-1 CS) further enhanced HIF-1α protein levels, whereas overexpression of a constitutively active SHP-1 (SHP-1 E74A) resulted in decreased HIF-1α levels during hypoxia, compared to wildtype SHP-1. Proteasome inhibition (MG132) returned HIF-1α levels to control or wildtype levels respectively in these cells. SHP-1 silencing did not alter HIF-1α mRNA levels. Finally, under hypoxic conditions SHP-1 knock-down enhanced intracellular endothelial reactive oxygen species (ROS) formation, as measured by oxidation of H2-DCF and DHE fluorescence.

Conclusions
SHP-1 decreases half-life of HIF-1α under hypoxic conditions resulting in decreased cell growth due to diminished VEGF synthesis and secretion. The regulatory effect of SHP-1 on HIF-1α stability may be mediated by inhibition of endothelial ROS formation stabilizing HIF-
1α protein. These findings highlight the importance of SHP-1 in hypoxic signaling and its potential as therapeutic target in ischemic diseases.

Introduction

Src homology region 2 domain-containing phosphatase-1 (SHP-1), a nonreceptor-type protein tyrosine phosphatase (PTP), is mainly expressed in hematopoietic cells and epithelial tissue like endothelial cells [1, 2]. We previously showed the importance of SHP-1 in endothelial function and homeostasis. We found SHP-1 to protect the endothelium from adhesion molecule upregulation and thrombosis under inflammatory conditions in vitro and in vivo [3]. Furthermore, another study from our group showed that SHP-1 also negatively regulates VEGF mediated endothelial cell signaling, by inhibiting the formation of reactive oxygen species (ROS) [2]. ROS is important for angiogenic processes and conditions where angiogenesis is induced, such as hypoxia or ischemia, are known to increase endothelial ROS formation [4]. Hypoxia dependent vessel sprouting (angiogenesis) is mediated by the transcription factor Hypoxia inducible factor-1 (HIF-1) [4–6], a major regulator of cellular adaption to hypoxia consisting of an oxygen dependently regulated α-subunit and a constitutively expressed β-subunit [7, 8]. Under normoxic conditions the HIF-1α subunit is marked for degradation by prolylhydroxylases and subsequently degraded by the proteasomal degradation system. Under hypoxic conditions however, the degradation is inhibited with accumulation of HIF-1α as a result [9, 10]. ROS have been shown to stabilize HIF-1α during hypoxia by preventing its degradation [11]. During hypoxia HIF-1 functions as a transcription factor for proteins such as the vascular endothelial growth factor (VEGF), which is of crucial importance for hypoxia driven endothelial cell proliferation. It has been shown that HIF-1 mediated VEGF secretion is essential for hypoxia induced endothelial cell proliferation by an autocrine loop mechanism [6, 12]. Interestingly, SHP-1 has been shown to inhibit endothelial cell proliferation and survival under hypoxic conditions [13, 14] and knock-down of SHP-1 results in improved angiogenesis in hindlimb ischemia [14]. Moreover, in vivo studies show the potential of SHP-1 inhibition to decrease necrosis size in myocardial infarction [15, 16] and ischemic stroke [17].

These findings highlight the importance of SHP-1 in hypoxia and ischemic diseases as well as its therapeutic potential. However, the mechanism how SHP-1 mediates these effects in hypoxia/ ischemia is not fully understood. In particular an involvement of SHP-1 in the regulation of HIF-1α has not yet been investigated.

In this study, we show that an inhibition of SHP-1 in human microvascular endothelial cells (HMEC) increases endothelial proliferation and VEGF secretion during hypoxia. Furthermore, we find that these effects were due to enhanced HIF-1α protein levels, possibly by enhanced ROS formation.

Materials and Methods

Chemicals

Mouse HIF-1α antibody used for immunoprecipitations was purchased from BD Biosciences (#610959, Heidelberg, Germany) and rabbit HIF-1α antibody used for western blotting was obtained from Merck Millipore (#04-1006,Darmstadt, Germany). Mouse (D-11, #sc-7289) and Rabbit (C-19, #sc-287) SHP-1 for immunoprecipitations and western blotting respectively and mouse VEGF (C-1, #sc-7269) antibodies were from Santa Cruz biotechnology (Heidelberg, Germany). Mouse phospho-tyrosine antibody was from Merck Millipore (# 05-321,
Darmstadt, Germany). Beta-Actin antibody was from Cell Signaling Technology (#4970, Danvers, MA, USA). Horseradish peroxidase-conjugated antibodies were from Calbiochem (Darmstadt, Germany) and fluorescently labeled secondary antibodies were from Invitrogen (Darmstadt, Germany). MG132 and Echinomycin were from Merck (Darmstadt, Germany). All other chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany).

**Cell lines and cell culture**

HMEC were provided by Ades et al.[18] and cultured as described previously [19]. HMEC were put on starvation medium (DMEM, 1% fetal calf serum) 24 hours prior to experiments unless stated otherwise.

**Hypoxic environment**

Cells were exposed to hypoxia in an appropriate chamber purchased from Cell Systems (Troisdorf, DE), which was flooded with 15–20 l/min of an anoxic gas mixture (5% CO₂, 95% N₂) for 4 minutes. The cell medium was bubbled with the same gas mixture for 30 minutes before usage. The hypoxia chamber was placed in an incubator at 37° C for either 4 or 24 hours. O₂ partial pressure in the cell medium reached an equilibrium after appr. 30–60 minutes at 8 plusmn;2 mmHg, which equals an O₂ concentration of 1±0.2%. This hypoxic environment was shown to induce HIF-1α expression after 4 hours, as well as VEGF synthesis and secretion after 24 hours.

**Transfection of antisense oligonucleotides (AS Odn)**

HMEC were transfected with specific SHP-1 AS Odn (5'-ccttgagcagggtctctgcatcc-3') or control Odn (5'-cccttatttactactttcgc-3') respectively in a concentration of 70 nM using the magnetofection method [20, 21] and the Effectene kit from Qiagen (Hilden, Germany) as previously described [2]. Odn were synthesized by Eurofins MWG Operon (Ebersberg, Germany). Experiments were performed 24 hours after transfection.

**Plasmid transfer**

HMEC were transfected with either SHP-1 wildtype, SHP-1 CS (dominant negative form due to mutation of Cys453 to Ser453 in the catalytic domain) or SHP-1 E74A (constitutively active form due to mutation of the Glu74 to Ala74 in the N-SH2 domain) plasmids using PeqFECT DNA (PEQLAB Biotechnologie Erlangen, Germany) according to the manufacturer’s protocol. Experiments were performed 48 to 72 hours after transfection. Plasmids were obtained from Addgene (www.addgene.org).

**Cell extracts for western blot analysis and immunoblotting**

Protein lysates were prepared and protein content quantified as described previously [2]. Lysates were then subjected to western blot analysis as described elsewhere [2].

**Immunofluorescence staining**

For immunofluorescent microscopy of SHP-1 and HIF-1α, cells were grown to confluence on 8-well microscope slides from IBIDI (Martinsried, Germany) and stained and visualized as previously described [22]. Quantification of fluorescent intensity was performed by pixel measurements using AxioVision 4.8 from Zeiss (Jena, Germany).
Immunoprecipitation
Immunoprecipitations were performed using μMACS Protein G MicroBeads and MACS separation columns from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the manufacturer’s protocol. The precipitates were quantified by western blotting.

Proliferation measurement
To quantify proliferation and cell viability protein concentrations of single wells of a 24-well plate were measured by Biuret method as previously described [2].

Quantification of VEGF synthesis and secretion
VEGF synthesis was determined by flow cytometry. Cells were exposed to hypoxia/normoxia without prior starvation. Subsequently, cells were detached using Accutase (PAA Laboratories, Pasching, Austria), pelleted, fixed with 5% formaldehyde solution for 10 min, pelleted, permeabilized with 0.1% Triton solution for 5 min, rinsed, incubated with VEGF antibody for 1 hour (1:200 in Phosphate buffered saline (Pbs) supplemented with calcium), rinsed and incubated with FITC labeled secondary antibody (1:400 in Pbs supplemented with calcium) for 30 min, pelleted and dissolved in Pbs supplemented with calcium for measurement by flow cytometry using a FACS Canto II (BD Biosciences, Heidelberg, Germany). To control for background staining, control cells were stained with secondary antibody only.

VEGF secretion in the supernatant was measured using Quantikine Human VEGF Immunoassay from R&D Systems (Minneapolis, MN, USA) according to the manufacturer’s protocol.

RNA isolation and quantitative real time PCR
Total RNA was isolated using the PeqGOLD total RNA kit (Peqlab Erlangen, Germany). A total of 2 μg RNA was transcribed to DNA by using SuperScript Reverse Transcriptase (Life Technologies, DE). Real time PCR was performed on TaqMan ABI 7700 (PE Applied Biosystems, Darmstadt, DE). TaqMan gene expression assays for HIF-1α (#Hs00153153_m1) and GAPDH (#4310884E) were used (Life Technologies, DE).

Measurement of reactive oxygen species (ROS)
Intracellular ROS formation was analyzed by quantifying the ROS dependent oxidation of H₂DCF to fluorescent DCF. Cells were incubated with 20 μM H₂DCF diacetate during normoxia/hypoxia, detached using Accutase (PAA Laboratories, Pasching, Austria), pelleted, rinsed and dissolved in PBS supplemented with calcium for instant measurement by flow cytometry using a FACS Canto II (BD Biosciences, Heidelberg, Germany). Superoxide production was detected by dihydroethidium (DHE) fluorescence. Cells were incubated with DHE (20 μM) during hypoxia/normoxia followed by detachment using Accutase (PAA Laboratories, Pasching, Austria). Cells were pelleted, rinsed and dissolved in PBS supplemented with calcium for instant measurement by flow cytometry using a FACS Canto II (BD Biosciences, Heidelberg, Germany). Median fluorescent units were used for the analysis.

Statistical analysis
Data were analyzed using Student’s t-test, Wilcoxon rank sum test or one-way ANOVA as appropriate. All data are presented as means ± SEM. Results were considered significant at an error probability level of $P < 0.05$. 
Results

Expression and localization of SHP-1 and HIF-1α in HMEC

First, we analyzed expression and localization of SHP-1 and HIF-1α in HMEC during normoxia and hypoxia. HIF-1α protein was induced by 1h and 4h hypoxia (western blot: n = 4, Fig. 1A). HIF-1α induction by 4h hypoxia could be confirmed by immunofluorescent staining (p<0.001; immunofluorescence: n = 6, Fig. 1B). On the contrary, SHP-1 protein was expressed during normoxic as well as hypoxic conditions but showed a slight increase in expression upon hypoxia (immunofluorescence: p<0.05; n = 6, Fig. 1B). Furthermore, analysis revealed that both proteins are predominantly located in the nucleus of HMEC with only moderate expression in the cytoplasm (n = 6, Fig. 1B). Additionally, immunoprecipitation of SHP-1 was performed and HIF-1α was detected in the precipitate (n = 6, Fig. 1C). SHP-1 protein could only be detected after performing immune precipitation with an antibody recognizing SHP-1 and not in 30μg of whole cell lysates indicating a relatively low expression level in endothelial cells. To investigate if HIF-1α is tyrosine phosphorylated in endothelial cells, immunoprecipitations of HIF-1α was performed followed by detection of phospho-tyrosine residues by western blot. As seen in Fig. 1D (upper blot lane 4), no HIF-1α was precipitated when using an IgG isotype control antibody and HIF-1α could successfully be precipitated when using a specific antibody (upper blot lane 6, n = 3). To analyze possible differences in HIF-1α tyrosine phosphorylation in normoxia and hypoxia, the immunoprecipitation was performed again in cells treated with the proteasome inhibitor MG132 to achieve equal HIF-1α amounts during both conditions. As seen in Fig. 1D (lower blot) HIF-1α is tyrosine phosphorylated but no difference between normoxia and hypoxia could be detected (n = 3).

SHP-1 regulates endothelial cell growth and VEGF synthesis during hypoxia

To investigate the role of SHP-1 on endothelial cell growth under hypoxic conditions SHP-1 was knocked-down by transfecting HMEC with specific antisense oligodesoxynucleotides (AS-Odn). The efficacy of this technique in endothelial cells has been described earlier by our group [2]. Silencing of SHP-1 led to increased cell growth during 24 hours of hypoxia (p<0.05; n = 18, Fig. 2A) compared to treatment with control AS-Odn (n = 18). As VEGF is known to be an important factor for endothelial proliferation [23] and its synthesis is enhanced by hypoxia [23–25], we also measured the intracellular VEGF concentration as well as VEGF secretion in the supernatant in dependence of SHP-1 expression. Knock-down of SHP-1 resulted in a significant increase in the amount of intracellular (p<0.05; n = 10, Fig. 2B) and secreted (p<0.01; n = 8, Fig. 2C) VEGF during 24h hypoxia compared to control AS-Odn treatment. Since HIF-1α is known to be an important mediator of hypoxia driven cellular responses and an important transcription factor for VEGF under these conditions [8] we next asked whether SHP-1 may regulate cell growth and VEGF production via the HIF-1 pathway. Treatment with echinomycin, a pharmacological inhibitor of HIF-1, during hypoxia completely abolished the increase in cell growth resulting from SHP-1 knock-down during 24h hypoxia (p<0.05; n = 11, Fig. 2D) in comparison to cells treated with control AS-Odn. Furthermore, the elevation of intracellular VEGF concentration (p<0.05; n = 10, Fig. 2B) as well as amount of secreted VEGF (p<0.05; n = 8, Fig. 2C) by SHP-1 knock-down was also prevented by echinomycin. Finally, this effect was confirmed when using another pharmacological inhibitor of HIF-1α, apigenin (p<0.05; n = 10, Fig. 2B and C).
SHP-1 Regulates HIF-1α in Endothelial Cells during Hypoxia

**A**

| hypoxia (h) | 0 | 1 | 4 |
|-------------|---|---|---|
| HIF-1α      |   |   |   |
| Actin       |   |   |   |

**B**

- **normoxia**
- **4h hypoxia**

- **HIF-1α**
- **SHP-1**
- **DAPI**
- **Merge**

Expression (fluorescence intensity pixel)

|          | H 4h |
|----------|------|
| HIF-1α   | +    |
| SHP-1    | -    |

**C**

- **Input 10%**
- **IP: SHP-1**

- **hypoxia 4h**
- **+**
- **-**
- **+**
- **-**

- **HIF-1α**
- **SHP-1**
- **Actin**

- **IP: SHP-1**
- **IB: HIF-1α, SHP-1, Actin**

**D**

- **Input 10%**
- **IP: HIF-1α**

- **hypoxia 4h**
- **-**
- **+**
- **+**
- **-**
- **+**

- **HIF-1α**
- **Actin**

- **IP: HIF-1α**
- **IB: HIF-1α, Actin**

**Input 10%**

- **IP: HIF-1α**
- **MG 132**
- **hypoxia 4h**
- **-**
- **+**
- **-**
- **+**

- **phospho-Tyr**
- **HIF-1α**
- **Actin**

- **IP: HIF-1α**
- **IB: phospho-Tyr, HIF-1α, Actin**
SHP-1 regulates HIF-1α protein levels during hypoxia in HMEC

As cell growth enhancement and increased VEGF synthesis by SHP-1 knock-down could be prevented by echinomycin, we next analyzed the effect of SHP-1 on HIF-1α protein levels. In cells treated with control AS-Odn hypoxia increased HIF-1α protein levels (n = 4, Fig. 3A), as expected. Interestingly, the induction of HIF-1α by hypoxia was even further enhanced by SHP-1 knock-down (p < 0.05; n = 4, Fig. 3A). To confirm these data, HMECs were transfected with pDNA expressing either wildtype (WT), catalytically inactive (CS) or constitutively active (E74A) SHP-1. Compared to cells expressing the SHP-1 WT construct, overexpression of the inactive SHP-1 mutant (CS) resulted in increased HIF-1α protein levels (p < 0.05; n = 8, Fig. 3B), whereas transfection with the constitutively active (E74A) SHP-1 construct led to decreased HIF-1α levels (p < 0.05; n = 9, Fig. 3B). Having observed an influence of SHP-1 activity on HIF-1α protein levels, we next investigated whether SHP-1 influences the synthesis or the degradation of HIF-1α. Consequently, we assessed the transcription of HIF-1α by qRT-PCR. As shown in Fig. 3C hypoxia itself decreased the amount of HIF-1α mRNA compared to normoxic controls (p < 0.05; n = 10), whereas SHP-1 knock-down had no additional effect in any of the two conditions (n = 10). Next, we analyzed translation and degradation of HIF-1α. As expected, treatment of HMEC with MG132 to block proteasomal degradation of HIF-1α further increased the amount of HIF-1α in hypoxic HMEC under control conditions (p < 0.05; n = 4, Fig. 3D). However, the additional increase in HIF-1α protein level previously observed after SHP-1 knock-down could no longer be detected upon treatment with MG132 (n = 4, Fig. 3D). Equivalent to this, after MG132 treatment of cells expressing SHP-1 CS HIF-1α levels were returned to WT levels (n = 8, Fig. 3E). In accordance to this, the lost HIF-1α accumulation in cells expressing E74A was rescued back to WT levels when inhibiting proteasomal degradation during hypoxia (n = 8, Fig. 3E).

SHP-1 regulates reactive oxygen species (ROS) formation in HMEC during hypoxia

As ROS have been shown to be essential for HIF-1α stability by inhibiting the activity of prolyl hydroxylases [11, 26, 27] and as we showed in a previous study that SHP-1 negatively regulates ROS production in non-stimulated and VEGF-treated EC [2], we hypothesized that SHP-1 may regulate the accumulation of HIF-1α protein by reducing ROS levels. Hence, we tested whether SHP-1 also effects endothelial ROS formation during hypoxia detecting the oxidation of H2DCF. SHP-1 silencing resulted in an increase in ROS formation (+ 15%) during hypoxia (p < 0.001; n = 12, Fig. 4A) compared to control treatment. As we previously showed that SHP-1 regulates VEGF dependent superoxide production, we next investigated if SHP-1 has an impact on superoxide production during hypoxia by detecting dihydroethidium (DHE) fluorescence. As shown in Fig. 4B, SHP-1 knock-down also increased superoxide levels during hypoxia compared to treatment with control AS (p < 0.05, n = 8).
Discussion

The nonreceptor-type protein tyrosine phosphatase SHP-1 has been recognized as potential target to treat ischemic diseases [14–17, 28, 29]. Regulatory processes in which SHP-1 is involved during hypoxia are not fully understood. This study adds new aspects to the role of SHP-1 in endothelial hypoxic signaling and further underlines its potential as therapeutic target in ischemic diseases. This is the first study to show that SHP-1 is not only involved in VEGF receptor signaling, but that it also plays a crucial role in VEGF synthesis and secretion during hypoxia by regulating the transcription factor HIF-1.

In vivo studies of other groups showed an increased expression of SHP-1 upon ischemia in myocardial [15] and muscle cells [14], as well as in astrocytes [30]. An ex-vivo study working with retinal explants did not see any changes in SHP-1 expression or activity upon hypoxia [31]. In this study, we could only detect a moderate influence of 4h hypoxia on SHP-1 expression in HMEC. The stronger induction of SHP-1 upon hypoxia observed by others might be cell type specific or might only occur after longer exposure to hypoxia and not in acute hypoxia (4h) as used here. However, acute hypoxia is of great interest as it reflects conditions occurring in acute arterial occlusion like myocardial infarction. Consistent with the fact that SHP-1 and HIF-1α contain a nuclear localization signal (NLS) [32, 33] our data show that both proteins are mainly located in the nucleus of the endothelial cells with moderate expression in the cytoplasm. SHP-1 protein could only be detected after concentration by immunoprecipitation. This is probably due to lower SHP-1 expression levels in endothelial cells. Indeed, SHP-1 has been described to mainly be expressed in hematopoietic cells and thus show lower expression in endothelial cells. Tyrosine phosphorylation of HIF-1α could be detected but did not change between normoxic and hypoxic conditions. As HIF-1α is degraded during normoxia, the tyrosine phosphorylation may not be important under these conditions. Under hypoxic conditions however, tyrosine phosphorylated HIF-1α may play a role, as HIF-1α accumulates and may so constitute a binding site for SH2-containing proteins, such as SHP-1. Interestingly, we could also detect HIF-1α in precipitates of SHP-1. Thus, both proteins may even be part of the same protein complex.

Upon SHP-1 silencing we observed increased endothelial cell growth under hypoxic conditions, which is in line with earlier studies [13, 14]. These earlier studies identified increased VEGFR-2 signaling [14] and increased expression of pro-angiogenic and anti-apoptotic factors [13] by SHP-1 knock-down, as being responsible for the observed effects highlighting the importance of SHP-1 as negative regulator of different pathways e.g. VEGF signaling. Here, we identified another aspect of how SHP-1 regulates endothelial cell growth during hypoxic conditions that has not been observed before. We found that SHP-1 inhibits synthesis of endothelial VEGF by accelerating HIF-1α protein degradation under hypoxic conditions. Our data show that SHP-1 knock-down increases intracellular and secreted VEGF. This is particularly interesting as endothelial VEGF is known to be crucial for hypoxia induced EC growth in terms of...
Fig 3. SHP-1 destabilizes HIF-1α protein during hypoxia. (A) HIF-1α protein levels were further enhanced by SHP-1 knock-down during hypoxia (4h) (*p<0.05, n = 4, lane 4) compared to control conditions (lane 3). Graph shows the protein band density of HIF-1α in relation to loading control β-Actin. (B) HIF-1α levels in non transfected cells was compared to SHP-1 WT expressing cells showing no influence of transfection on this (upper blot; n = 4). HMECs expressing inactive SHP-1 (CS) showed increased (*p<0.05; n = 8, lane 2 in lower blot), whereas expression of constitutively active SHP-1 (E74A) showed decreased (*p<0.05; n = 9, lane 3 in lower blot) levels of HIF-1α compared to wildtype (WT) SHP-1 (lane 1 in lower blot). Graph shows HIF-1α protein band density in relation to the loading control β-Actin. (C) HIF-1α mRNA was quantified by qRT-PCR. Hypoxia (4h) significantly decreased HIF-1α mRNA compared to normoxic conditions (*p<0.05; n = 10). However, SHP-1 knock-down had no effect on HIF-1α mRNA levels (n = 10). (D) The regulatory effect of SHP-1 on HIF-1α levels shown in (A) could not be observed when protein degradation was prevented by using the proteasome inhibitor MG132 (10μM) (n = 4). Graph shows HIF-1α protein band density in relation to the loading control β-Actin. (E) Differences in HIF-1α translation between cells expressing catalytic inactive (CS) and wildtype (WT) SHP-1 were not detected (n = 8) and the decreased HIF-1α accumulation seen in cells expressing constitutively active (E74A) SHP-1 was rescued upon inhibition of proteasomal inhibition (MG132 10μM) (n = 8).

doi:10.1371/journal.pone.0121113.g003
Fig 4. SHP-1 knock-down enhances ROS production during hypoxia. (A) SHP-1 knock-down enhanced ROS formation during hypoxia (*p<0.001; n = 12) compared to control AS-Odn treated cells. (B) SHP-1 knock-down enhanced hypoxia induced intracellular superoxide production (*p<0.05, n = 8), as assessed by DHE fluorescence.

doi:10.1371/journal.pone.0121113.g004
an autocrine loop mechanism \[6, 12\]. Furthermore, hypoxia has been shown to enhance the expression of the VEGF receptors \[34, 35\], which also contributes to the increased proliferative response during this condition. Cell growth and VEGF synthesis during hypoxia were impaired by echinomycin and apigenin, both pharmacological inhibitors of HIF-1α activity \[36\], indicating that both increased cell growth and VEGF synthesis are, at least partially, HIF-1α mediated. Interestingly, inhibition of HIF-1α by echinomycin completely blocked VEGF synthesis and secretion, whereas apigenin was shown to have a greater effect on VEGF synthesis and to a lesser extent, although still significant, on VEGF secretion. The same phenomenon can be seen in other studies using apigenin \[37, 38\], an effect which may be concentration dependent, as seen in the study of Mirzoeva et al. \[38\]. Nevertheless, the increase in hypoxic cell growth, VEGF synthesis and secretion by SHP-1 knock-down could be prevented by HIF-1α inhibition using echinomycin and apigenin, suggesting that SHP-1 is part of these HIF-1α dependent processes.

Analyzing the role of SHP-1 on HIF-1α protein levels we found that SHP-1 knock-down indeed further enhanced the induction of HIF-1α by hypoxia. The same results were obtained transfecting HMEC with an inactive SHP-1 construct. These findings were in accordance with the fact that expression of a construct containing a constitutively active SHP-1 decreased HIF-1α levels compared to expression of the wildtype construct. This experiment further confirms that the catalytic activity of SHP-1 is responsible for the observed effect and not merely expression of the protein. To the best of our knowledge this is the first time an explicit role of SHP-1 on HIF-1α induction in hypoxia and in endothelial cells is described. When investigating whether SHP-1 influences synthesis or degradation of HIF-1α we found that neither in normoxia nor in hypoxia SHP-1 knock-down seemed to influence HIF-1α transcription. However, upon inhibition of the HIF-1α degradation pathway, to investigate effects on translation as well as degradation, a difference in HIF-1α levels between SHP-1 knock-down cells and control cells or SHP-1 WT and SHP-1 CS expressing cells respectively could no longer be detected. This demonstrates that SHP-1 does not influence the translation of HIF-1α protein. Furthermore, as the decrease in HIF-1α levels in cells expressing constitutively active SHP-1 could be rescued by MG132 treatment, SHP-1 rather influences the degradation of HIF-1α. Regarding the mechanism how SHP-1 influences HIF-1α protein levels we know from previous studies that reactive oxygen species (ROS) stabilize HIF-1α under hypoxic \[11, 26, 27\] and normoxic \[39–42\] conditions. Previous data from our group showed that SHP-1 is a negative regulator of endothelial ROS formation under normoxic conditions \[2\]. In this study we could show that SHP-1 silencing also increases intracellular ROS formation, particularly superoxide molecules, during hypoxia. Hence, it is possible and plausible that the negative regulatory effect of SHP-1 on HIF-1α is the result of SHP-1 inhibiting endothelial ROS formation. The exact mechanism behind this regulation still needs to be elucidated and is part of our further research.

We conclude that SHP-1 promotes HIF-1α degradation under hypoxic conditions leading to a reduction in VEGF synthesis and secretion and thus impaired EC proliferation. A negative regulation of ROS by SHP-1 may have a potential mediator role in this signaling cascade. SHP-1 seems to prevent cellular overstimulation under hypoxic conditions and, hence, may be of importance in proliferative diseases e.g. in tumor angiogenesis. Finally, as inhibition of SHP-1 activity under hypoxia seems to be proangiogenic, SHP-1 may indeed constitute an interesting therapeutic target for ischemic diseases.

**Acknowledgments**

Special thanks go to Ramona Mettler for her valuable help for this work.
Author Contributions
Conceived and designed the experiments: SA FK HM YS. Performed the experiments: SA YS RR EG AR MW. Analyzed the data: SA HM MW YS RR EG AR JP. Contributed reagents/materials/analysis tools: HM MW FK. Wrote the paper: SA HM FK JP YS.

References
1. Lopez-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colas B. SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem. 2011; 11(1):89–98. PMID: 21291405
2. Kroetz F, Engelbrecht B, Buerkle MA, Basser mann F, Bridell H, Gloe T, et al. The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J Am Coll Cardiol. 2005; 45(10):1700–6. doi: 10.1016/j.jacc.2005.02.039 PMID: 15893190
3. Koch E, Pircher J, Czermak T, Gaitzsch E, Alig S, Mannell H, et al. The endothelial tyrosine phosphatase SHP-1 plays an important role for vascular haemostasis in TNFalpha -induced inflammation in vivo. Mediators Inflamm. 2013; 2013:279781. doi: 10.1155/2013/279781 PMID: 23766558
4. Fraisil P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell. 2009; 16(2):167–79. doi: 10.1016/j.devcel.2009.01.003 PMID: 19217420
5. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003; 63(19):6130–4. PMID: 14559790
6. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004; 6(5):485–95. doi: 10.1016/j.ccr.2004.09.026 PMID: 15542432
7. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148(3):399–408. doi: 10.1016/j.cell.2012.01.021 PMID: 22304911
8. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000; 88(4):1474–80. PMID: 10749844
9. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. J Cell Sci. 2009; 122(Pt 8):1055–7. doi: 10.1242/jcs.035022 PMID: 19339544
10. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002; 64(5–6):993–6.
11. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ. 2008; 15(4):660–6. doi: 10.1038/sj.cdd.4402307 PMID: 18219320
12. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007; 130(4):691–703. doi: 10.1016/j.cell.2007.06.054 PMID: 17719546
13. Cho SW, Harte L, Son SM, Yang F, Goldberg M, Xu Q, et al. Delivery of small interfering RNA for inhibition of endothelial cell apoptosis by hypoxia and serum deprivation. Biochem Biophys Res Commun. 2008; 376(1):158–63. doi: 10.1016/j.bbrc.2008.08.123 PMID: 18765230
14. Sugano M, Tsuchida K, Maeda T, Makino N. SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia. Atherosclerosis. 2007; 191(1):33–9. doi: 10.1016/j.atherosclerosis.2006.04.021 PMID: 16725144
15. Sugano M, Tsuchida K, Hata T, Makino N. RNA interference targeting SHP-1 attenuates myocardial infarction in rats. FASEB J. 2005; 19(14):2054–6. doi: 10.1096/fj.05-4020fje PMID: 16223786
16. Kim D, Hong J, Moon HH, Nam HY, Mok H, Jeong JH, et al. Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. J Control Release. 2013; 168(2):125–34. doi: 10.1016/j.jconrel.2013.02.031 PMID: 23500061
17. Beamer CA, Brooks DM, Lurie DI. Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia. J Neurosci Res. 2006; 83(7):1220–30. doi: 10.1002/jnr.20825 PMID: 16528752
18. Ades EW, Candal FJ, Swertlick RA, George VG, Summers S, Bosse DC, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992; 99(6):683–90. PMID: 1361507
19. Mannell H, Hellwig N, Gloe T, Plank C, Sohn HY, Groesser L, et al. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res. 2008; 45(2):153–63. doi: 10.1159/000110081 PMID: 17962719
20. Krotz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, et al. Magnetofection—a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther. 2003; (5 Pt 1):700–10. PMID: 12718913

21. Krotz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res. 2003; 40(5):425–34. doi: 10.1159/000073901 PMID: 14530599

22. Mannell H, Hammitzsch A, Mettler R, Pohl U, Krotz F. Suppression of DNA-PKcs enhances FGF-2 dependent human endothelial cell proliferation via negative regulation of Akt. Cell Signal. 2010; 22(1):88–96. doi: 10.1016/j.cellsig.2009.09.015 PMID: 19781633

23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18 (1):4–25. PMID: 9034784

24. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 1996; 94(7):1647–54. PMID: 8840857

25. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998; 95 (20):11715–20. PMID: 9751731

26. Chandel NS, McClinton DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000; 275(33):25130–8. doi: 10.1074/jbc.M001914200 PMID: 10833514

27. Won YW, Lee M, Kim HA, Bull DA, Kim SW. Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease. J Control Release. 2012. doi: 10.1016/j.jconrel.2012.10.014.

28. Rhim T, Lee DY, Lee M. Hypoxia as a target for tissue specific gene therapy. J Control Release. 2013; 172(2):484–94. doi: 10.1016/j.jconrel.2013.05.021 PMID: 23742881

29. Wischcamper CA, Brooks DM, Douglas Coffin J, Lurie DI. Focal cerebral ischemia upregulates SHP-1 in reactive astrocytes in juvenile mice. Brain Res. 2003; 974(1–2):88–98. doi: 10.1016/s0006-8993(03)02564-2 PMID: 12742645

30. Mei S, Cammalleri M, Azara D, Casini G, Bagnoli P, Dal Monte M. Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J Pathol. 2012; 226(3):519–33. doi: 10.1002/path.3006 PMID: 21960021

31. Craggs G, Kellie S. A functional nuclear localization sequence in the C-terminal domain of SHP-1. J Biol Chem. 2001; 276(26):23719–25. doi: 10.1074/jbc.M102846200 PMID: 11323437

32. Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, Tanaka H, et al. Signal transduction in hypoxic endothelial cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998; 17(22):6573–82. doi: 10.1093/emboj/17.22.6573 PMID: 9822602

33. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 1996; 94(7):1647–54. PMID: 8840857

34. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997; 272(38):23659–67. PMID: 9295307

35. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65(19):9047–55. doi: 10.1158/0008-5472.can-05-1235 PMID: 16204079

36. Chao SC, Huang SC, Hu DN, Lin HY. Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways. Evid Based Complement Alternat Med. 2013; 2013:817674. doi: 10.1155/2013/817674 PMID: 24288566

37. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog. 2008; 47(9):686–700. doi: 10.1002/mc.20241 PMID: 18240292

38. Patten DA, Lafleur VN, Robitaille GA, Chan DA, Giaccia AJ, Richard DE. Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species. Mol Biol Cell. 2010; 21(18):3247–57. doi: 10.1091/mbc.E10-01-0025 PMID: 20660157
40. Nishi K, Oda T, Takabuchi S, Oda S, Fukuda K, Adachi T, et al. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal. 2008; 10(5):983–95. doi:10.1089/ars.2007.1825 PMID: 18199003

41. Moon EJ, Sonveaux P, Porporato PE, Danhier P, Gallez B, Batinic-Haberle I, et al. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci U S A. 2010; 107(47):20477–82. doi:10.1073/pnas.1006646107 PMID: 21059928

42. Lee HY, Lee T, Lee N, Yang EG, Lee C, Lee J, et al. Src activates HIF-1alpha not through direct phosphorylation of HIF-1alpha specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway. Carcinogenesis. 2011; 32(5):703–12. doi:10.1093/carcin/bgr034 PMID: 21335603